Advancing Aminoadamantane-based Therapeutics for CNS Disorders
Adamas Pharmaceuticals, based in Emeryville, California with operations in Bangalore, India, is the leading developer of aminoadamantane-based therapeutics for CNS disorders. The company's research and development platform is focused on developing controlled release versions and optimized fixed dose combinations of aminoadamantanes to address major dosing and titration challenges that limit the use of currently available therapeutics. Adamas is advancing two programs from this platform through Phase 3 clinical studies, including Nurelin (amantadine HCl extended release capsules), initially for levodopa-induced dyskinesia in patients with Parkinson's disease and Arimenda (memantine HCl extended release and donepezil HCl) capsules for Alzheimer's disease. Both products are designed to improve tolerability and clinical efficacy, and to provide superior clinical and health economic benefits.
Facts & Stats
- Aminoadamantanes were first synthesized in the 1950s and include FDA-approved amantadine, rimantadine and memantine.
- Over 6 million people in the U.S. suffer from chronic neurodegenerative diseases such as dementia and Parkinson’s disease.
- Adamas is developing Advantaged Therapeutics for dementia and Parkinson’s disease that are designed to provide improved efficacy and tolerability and to simplify daily drug regimens.